Compare Incyte Corporation (INCY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance

Incyte CorporationTrade

YieldMax Magnificent 7 Fund of Option Income ETFsTrade

Price performance (Past 24H)

Key statistics

Incyte Corporation vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.67. The key difference: Incyte Corporation is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.

	INCY	YMAG
Market Cap	$23.11B	—
Sector	Health	Income / Options Overlay
52-Week High	$118.52	$15.98
52-Week Low	$67.38	$11.00
Enterprise Value	$19.13B	—

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INCY

Over 180 companies develop 200+ PD-1/PD-L1 inhibitors, reshaping cancer treatment landscape.Delveinsight · 5 hours agoBullish View details →

YMAG

YieldMax ETFs declare weekly distributions for multiple option income ETFs starting July 23, 2026.Na · 11 hours agoNeutral View details →

About Incyte Corporation

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.

About YieldMax Magnificent 7 Fund of Option Income ETFs

YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.